Biopharma Has Been Fast To Adopt AI/ML, But It’s Unclear How It Will Play Out

 
• By Alaric DeArment
  
L-R: moderator Rachel Ravens, managing partner, 46Health; Martin Akerman, chief technology officer, Envisagenics; Ahmet-Hamdi Çavuşoğlu, senior director, Merck Digital Sciences Studio; Vitalay Fomin, CEO, Numenos (Alaric DeArment)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from AI

More from Digital Technologies